Proactive Investors - Run By Investors For Investors

Sativa Investments teams up with King's College London to research cannabinoids for medicinal use

Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids
cannabis
Sativa is the UK's first medicinal cannabis investment vehicle

UK medicinal cannabis investor Sativa Investments PLC (NEX: SATI) has teamed up with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases. 

Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids, subject to regulatory approval.

READ: Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility

Sativa will provide the service through investee business, Canada-based Veritas Pharma Inc, and its own on-site testing facility, PhytoVista Laboratories.

Professor Clive Page OBE PhD Professor of Pharmacology at King's College London will lead the research.

"With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King's College London will assist the medical profession, Government and Regulators in their deliberations,” said Sativa founder and chief executive, Geremy Thomas.

"As the UK's first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Group PLC Timeline

Related Articles

PT exercises
December 20 2018
The Californian company is a bet on an industry that is in need of transformation
Social media use
April 19 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
microscope
May 01 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use